A J Zurita1, D J George2, N D Shore3, G Liu4, G Wilding4, T E Hutson5, M Kozloff6, P Mathew7, C S Harmon8, S L Wang9, I Chen10, E Chow Maneval10, C J Logothetis7. 1. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. Electronic address: azurita@mdanderson.org. 2. Divisions of Medical Oncology and Urology, Duke University Medical Center, Durham. 3. Carolina Urologic Research Center, Myrtle Beach. 4. Hematology/Oncology Division, University of Wisconsin Carbone Cancer Center, Madison. 5. Genitourinary Oncology Program, Baylor Sammons Cancer Center-Texas Oncology, P.A., Dallas. 6. Cancer Research Center, Ingalls Memorial Hospital, Harvey. 7. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. 8. Departments of Translational Oncology. 9. Departments of Clinical Statistics. 10. Departments of Clinical Development, Pfizer Oncology, La Jolla, USA.
Abstract
BACKGROUND: This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS: To determine the recommended phase 2 dose (RP2D), 25 patients in four dose escalation cohorts received 3-week cycles of sunitinib (2 weeks on, 1 week off), docetaxel and prednisone, preceded by a 4-week sunitinib 50 mg/day lead in. RP2D was evaluated in 55 additional patients. The primary end point was prostate-specific antigen (PSA) response rate. RESULTS: One phase 1 dose-limiting toxicity occurred (grade 3 hyponatremia). The RP2D was sunitinib 37.5 mg/day, docetaxel 75 mg/m(2) and prednisone 5 mg b.i.d. During phase 2, confirmed PSA responses occurred in 31 patients [56.4% (95% confidence interval 42.3-69.7)]. Median time to PSA progression was 9.8 months. Forty-one patients (75%) were treated >3 months, 12 (22%) completed the study (16 cycles) and 43 (78%) discontinued (36% for disease progression and 27% adverse events). The most frequent treatment-related grade 3/4 adverse events were neutropenia (53%; 15% febrile) and fatigue/asthenia (16%). Among 33 assessable patients, 14 (42.4%) had confirmed partial response. Median progression-free and overall survivals were 12.6 and 21.7 months, respectively. CONCLUSION: This combination was moderately well tolerated, with promising response rate and survival benefit, justifying further investigation in mCRPC.
BACKGROUND: This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS: To determine the recommended phase 2 dose (RP2D), 25 patients in four dose escalation cohorts received 3-week cycles of sunitinib (2 weeks on, 1 week off), docetaxel and prednisone, preceded by a 4-week sunitinib 50 mg/day lead in. RP2D was evaluated in 55 additional patients. The primary end point was prostate-specific antigen (PSA) response rate. RESULTS: One phase 1 dose-limiting toxicity occurred (grade 3 hyponatremia). The RP2D was sunitinib 37.5 mg/day, docetaxel 75 mg/m(2) and prednisone 5 mg b.i.d. During phase 2, confirmed PSA responses occurred in 31 patients [56.4% (95% confidence interval 42.3-69.7)]. Median time to PSA progression was 9.8 months. Forty-one patients (75%) were treated >3 months, 12 (22%) completed the study (16 cycles) and 43 (78%) discontinued (36% for disease progression and 27% adverse events). The most frequent treatment-related grade 3/4 adverse events were neutropenia (53%; 15% febrile) and fatigue/asthenia (16%). Among 33 assessable patients, 14 (42.4%) had confirmed partial response. Median progression-free and overall survivals were 12.6 and 21.7 months, respectively. CONCLUSION: This combination was moderately well tolerated, with promising response rate and survival benefit, justifying further investigation in mCRPC.
Authors: D Wu; H E Zhau; W-C Huang; S Iqbal; F K Habib; O Sartor; L Cvitanovic; F F Marshall; Z Xu; L W K Chung Journal: Oncogene Date: 2007-02-19 Impact factor: 9.867
Authors: Hisanori Uehara; Sun Jin Kim; Takashi Karashima; David L Shepherd; Dominic Fan; Rachel Tsan; Jerald J Killion; Christopher Logothetis; Paul Mathew; Isaiah J Fidler Journal: J Natl Cancer Inst Date: 2003-03-19 Impact factor: 13.506
Authors: Barbara Sennino; Frank Kuhnert; Sebastien P Tabruyn; Michael R Mancuso; Dana D Hu-Lowe; Calvin J Kuo; Donald M McDonald Journal: Cancer Res Date: 2009-04-28 Impact factor: 12.701
Authors: O Guérin; P Formento; C Lo Nigro; P Hofman; J L Fischel; M C Etienne-Grimaldi; M Merlano; J M Ferrero; G Milano Journal: J Cancer Res Clin Oncol Date: 2007-06-26 Impact factor: 4.553
Authors: Paul Mathew; Peter F Thall; Corazon D Bucana; William K Oh; Michael J Morris; Donnah M Jones; Marcella M Johnson; Sijin Wen; Lance C Pagliaro; Nizar M Tannir; Shi-Ming Tu; Anthony A Meluch; Lon Smith; Lorenzo Cohen; Sun-Jin Kim; Patricia Troncoso; Isaiah J Fidler; Christopher J Logothetis Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: A J Armstrong; S Halabi; P Healy; W R Lee; B F Koontz; J W Moul; K Mundy; P Creel; S Wood; K Davis; M A Carducci; M Stein; C Hobbs; B Reimer; M Nguyen; M Anand; L Bratt; S Kim; P T Tran; D J George Journal: Prostate Cancer Prostatic Dis Date: 2016-01-12 Impact factor: 5.554
Authors: Srikala S Sridhar; Anthony M Joshua; Richard Gregg; Christopher M Booth; Nevin Murray; Jovana Golubovic; Lisa Wang; Pamela Harris; Kim N Chi Journal: Clin Genitourin Cancer Date: 2014-06-08 Impact factor: 2.872
Authors: Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Date: 2014-05-14 Impact factor: 3.641
Authors: Nicolas Kozakowski; Caroline Hartmann; Hans Christoph Klingler; Martin Susani; Peter R Mazal; Anke Scharrer; Andrea Haitel Journal: Target Oncol Date: 2013-11-17 Impact factor: 4.493